Este estudio explora una nueva técnica llamada Ultrasonido Enfocado (FUS) para ayudar a personas con problemas de uso de opioides u otras sustancias. Esta técnica se dirige a una parte específica del cerebro conocida como NAc/VC, que puede estar involucrada en el deseo y los comportamientos de uso de sustancias. El estudio tiene como objetivo determinar si este método puede reducir el deseo de drogas en estas personas. Esta investigación es importante porque podría llevar a nuevas formas de tratar los trastornos por uso de sustancias, que son difíciles de manejar con los métodos actuales. Los participantes en el estudio primero pasarán por un proceso de selección para asegurarse de que sean aptos para el tratamiento. Una vez que sean elegibles, recibirán el tratamiento con FUS dirigido a ambos lados del área NAc/VC del cerebro. Durante el estudio, habrá evaluaciones para medir su comportamiento y deseos antes, durante y después del tratamiento. Las visitas de seguimiento están programadas para el Día 1 y en las Semanas 1, 4, 8 y 12 para monitorear los cambios y recopilar datos sobre los efectos del tratamiento. El estudio no especifica beneficios o riesgos particulares, pero tiene como objetivo proporcionar información sobre el potencial del FUS como tratamiento para los trastornos por uso de sustancias.
Inclusion Criteria: * Aged 22 - 60 years at time of enrollment. * Fulfill current DSM-5 diagnostic criteria for OUD and/or other SUDs with at least a 2-year history. * Currently receiving outpatient treatment from the WVU Comprehensive Opioid Addiction * Treatment Program (COAT), Intensive Outpatient Program (IOP) or any other program which implements the COAT model; or receiving outpatient/inpatient/residential treatment from similar SUD treatment programs. * Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers. * Agrees to allow any and all forms of communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event. Exclusion Criteria: * Unable to undergo MR-imaging because of non-MR compatible implants or if candidates are uncomfortable in small spaces (have claustrophobia). * History of any clinically significant neurological disorder. * History of stroke or brain lesion with observable structural abnormalities in the targeted brain region. * Clinically significant MRI abnormality indicative of a neurological condition or abnormality that may jeopardize the participant's safety, study conduct, or confound the participant's diagnostic assessments. * An abnormal screening result that is considered clinically significant by a medically qualified research team member (i.e., laboratory tests, imaging findings). * More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp. * Past or present diagnosis of schizophrenia or psychotic disorder (assessed via SCID- * History of medically verified suicide attempt within the past year. * Meet the criteria for Cluster A or B Personality Disorders (assessed via SCID-5-PD). * Current substance use treatment mandated by court of law. * Subject who is currently participating in another clinical investigation with an active * treatment arm. * Subject is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator
está designado en este estudio
de ser asignado al grupo placebo